podophyllotoxin has been researched along with Neutropenia in 13 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (23.08) | 18.7374 |
| 1990's | 5 (38.46) | 18.2507 |
| 2000's | 1 (7.69) | 29.6817 |
| 2010's | 3 (23.08) | 24.3611 |
| 2020's | 1 (7.69) | 2.80 |
| Authors | Studies |
|---|---|
| Barbon Gauro, J; Heng, MS; Thomas, J; Yaxley, A | 1 |
| Abrahmsen, L; Alvfors, C; Axelson, M; Bergqvist, M; Bergström, S; Ekman, S; Eksborg, S; Frödin, JE; Harmenberg, J; Hedlund, Å; Jerling, M; Larsson, O; Ståhl, B; Wassberg, C | 1 |
| Asmar, L; Beveridge, R; Boehm, KA; Mandanas, R; McGaughey, D; Orloff, G; Rifkin, R; Spitzer, G; Zhan, F | 1 |
| Buset, EM; Haile, SR; Honegger, H; Knuth, A; Mischo, A; Pestalozzi, BC; Petrausch, U; Renner, C; Samaras, P; Schanz, U; Siciliano, RD; Stahel, RA; Stenner-Liewen, F; Stussi, G | 1 |
| Atkins, H; Bence-Bruckler, I; Bredeson, C; Huebsch, L; Leger, C; McDiarmid, S; Sabloff, M; Zhang, H | 1 |
| Greco, FA; Hainsworth, JD; Johnson, DH; Wolff, SN | 1 |
| Bodey, GP; Cabanillas, F; Freireich, EJ; Hagemeister, FB | 1 |
| Brandwein, JM; Colwill, R; Couture, F; Crump, M; Danish, R; Keating, A; Scott, JG; Stewart, AK; Sutcliffe, SB; Sutton, DM | 1 |
| Cavalli, F; D'Incalci, M; De Fusco, M; de Jong, J; Hanauske, A; Kaeser-Fröhlich, A; Pagani, O; Sessa, C; Zucchetti, M | 1 |
| Hanauske, AR; Kaeser-Fröhlich, A; Rassmann, I; Rastetter, J; Schilling, T; Schrödel, H; Zucchetti, M | 1 |
| Cooper, DL; D'Andrea, E; Hu, GL; Jillella, AP; Nadkarni, R; Salloum, E; Seropian, S; Zelterman, D | 1 |
| Burtness, B; Cooper, DL; Hu, GL; Jillella, AP; Nadkarni, R; Salloum, E; Seropian, S; Zelterman, D | 1 |
| Dang, P; Deboer, G; Evans, WK; Feld, R; Osoba, D; Shepherd, FA | 1 |
6 trial(s) available for podophyllotoxin and Neutropenia
| Article | Year |
|---|---|
A novel oral insulin-like growth factor-1 receptor pathway modulator and its implications for patients with non-small cell lung carcinoma: A phase I clinical trial.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Female; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Molecular Targeted Therapy; Neutropenia; Podophyllotoxin; Prospective Studies; Receptor, IGF Type 1; Signal Transduction; Treatment Outcome | 2016 |
Pegfilgrastim appears equivalent to daily dosing of filgrastim to treat neutropenia after autologous peripheral blood stem cell transplantation in patients with non-Hodgkin lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Cytarabine; Etoposide; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Neoplasm Staging; Neutropenia; Podophyllotoxin; Polyethylene Glycols; Recombinant Proteins; Transplantation, Autologous; Young Adult | 2010 |
Outpatient autologous hematopoietic stem cell transplantation for patients with relapsed follicular lymphoma.
Topics: Adult; Aged; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Cytarabine; Disease-Free Survival; Etoposide; Female; Follow-Up Studies; Gastrointestinal Diseases; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Follicular; Male; Melphalan; Middle Aged; Neutropenia; Podophyllotoxin; Retrospective Studies; Transplantation Conditioning; Transplantation, Autologous | 2006 |
Mini-BEAM as salvage therapy for relapsed or refractory Hodgkin's disease before intensive therapy and autologous bone marrow transplantation.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Confidence Intervals; Critical Care; Cytarabine; Erythrocyte Transfusion; Female; Follow-Up Studies; Hodgkin Disease; Humans; Male; Melphalan; Middle Aged; Neutropenia; Platelet Transfusion; Podophyllotoxin; Preoperative Care; Prognosis; Recurrence; Salvage Therapy; Time Factors | 1995 |
Clinical and pharmacokinetic study of oral NK611, a new podophyllotoxin derivative.
Topics: Administration, Oral; Adrenal Gland Neoplasms; Adult; Aged; Antineoplastic Agents; Area Under Curve; Biological Availability; Bone Neoplasms; Carcinoma, Non-Small-Cell Lung; Disease Progression; Drug Administration Schedule; Female; Humans; Injections, Intravenous; Lung Neoplasms; Male; Middle Aged; Neoplasms; Neutropenia; Podophyllotoxin; Thrombocytopenia | 1996 |
Clinical and pharmacokinetic phase I trial of oral dimethylaminoetoposide (NK611) administered for 21 days every 35 days.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Cell Count; Drug Administration Schedule; Female; Humans; Leukopenia; Male; Middle Aged; Neoplasms; Neutropenia; Podophyllotoxin | 1996 |
7 other study(ies) available for podophyllotoxin and Neutropenia
| Article | Year |
|---|---|
Does a neutropenic diet reduce adverse outcomes in patients undergoing chemotherapy?
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bacteremia; Bacterial Infections; Carmustine; Chemotherapy-Induced Febrile Neutropenia; Cytarabine; Diet Therapy; Enterocolitis, Neutropenic; Female; Hematologic Neoplasms; Humans; Idarubicin; Male; Melphalan; Middle Aged; Neutropenia; Podophyllotoxin; Retrospective Studies; South Australia | 2020 |
Equivalence of pegfilgrastim and filgrastim in lymphoma patients treated with BEAM followed by autologous stem cell transplantation.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Drug Administration Schedule; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Hodgkin Disease; Humans; Length of Stay; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Neutropenia; Peripheral Blood Stem Cell Transplantation; Podophyllotoxin; Polyethylene Glycols; Recombinant Proteins; Severity of Illness Index; Thrombocytopenia; Time Factors; Transplantation, Autologous; Treatment Outcome; Young Adult | 2010 |
High-dose VP-16-213 monotherapy for refractory germinal malignancies: a phase II study.
Topics: Adolescent; Adult; Bone Marrow; Bone Marrow Transplantation; Chemical and Drug Induced Liver Injury; Choriocarcinoma; Combined Modality Therapy; Drug Evaluation; Drug Resistance; Dysgerminoma; Etoposide; Female; Humans; Male; Nausea; Neutropenia; Podophyllotoxin; Pregnancy; Teratoma; Vomiting | 1984 |
IMVP-16: an effective regimen for patients with lymphoma who have relapsed after initial combination chemotherapy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bacterial Infections; Cyclophosphamide; Drug Therapy, Combination; Etoposide; Humans; Ifosfamide; Inflammation; Lymphoma; Methotrexate; Mucous Membrane; Neutropenia; Podophyllotoxin; Recurrence | 1982 |
Assessment of pulmonary and cardiac function after high dose chemotherapy with BEAM and peripheral blood progenitor cell transplantation.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Therapy; Cytarabine; Female; Heart; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Lung; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Neutropenia; Neutrophils; Podophyllotoxin; Respiratory Function Tests; Retrospective Studies; Ventricular Function, Left | 1998 |
Neutropenic infections in 100 patients with non-Hodgkin's lymphoma or Hodgkin's disease treated with high-dose BEAM chemotherapy and peripheral blood progenitor cell transplant: out-patient treatment is a viable option.
Topics: Adult; Ambulatory Care; Antibiotic Prophylaxis; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Dose-Response Relationship, Drug; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Lymphoma, Non-Hodgkin; Melphalan; Middle Aged; Neutropenia; Podophyllotoxin; Retrospective Studies | 1999 |
VP-16 and cisplatin as first-line therapy for small-cell lung cancer.
Topics: Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carcinoma, Small Cell; Cisplatin; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neutropenia; Podophyllotoxin; Thrombocytopenia; Time Factors | 1985 |